Medication Side Effects and Interactions in the Emergency Department: High-Yield FRCEM SBA Practice Questions Explained

Adverse drug reactions (ADRs) and clinically significant drug interactions account for an estimated 6.5% of all unplanned hospital admissions in the UK, a figure that has remained stubbornly consistent since the landmark Pirmohamed et al. study published in The BMJ in 2004. Emergency physicians encounter iatrogenic illness daily, frequently before a complete medication history is available and almost always without the luxury of time. For trainees preparing FRCEM SBA practice questions, this topic sits at the intersection of pharmacology, clinical reasoning, and patient safety, making it one of the most intellectually demanding and consistently examined domains across the RCEM curriculum.

Epidemiology and Clinical Relevance in UK Emergency Medicine

Polypharmacy, defined by NICE as the concurrent use of five or more regular medications, is present in over 40% of adults aged 65 and over in the UK. This demographic accounts for a disproportionate share of ED attendances, and the combination of age-related pharmacokinetic changes (reduced renal clearance, altered hepatic metabolism, lower albumin concentrations affecting protein binding) and polypharmacy creates fertile ground for iatrogenic illness. Anticoagulants, antiplatelet agents, diuretics, antidiabetic drugs, opioids, and cardiovascular medications collectively represent the drug classes most frequently implicated in preventable harm. For the FRCEM SBA exam, understanding which combinations generate risk, rather than memorising exhaustive lists, is the more transferable and examinable skill.

The RCEM curriculum explicitly identifies the recognition and management of ADRs as a core competency at both registrar and consultant level. Presentations span the full clinical spectrum: from the patient with a supratherapeutic INR and haematuria, to the confused older adult with lithium toxicity precipitated by a newly commenced NSAID, to the young woman in cardiovascular collapse following inadvertent serotonin syndrome. Each scenario rewards the candidate who can apply mechanistic understanding rather than pattern-match from rote memory.

Pathophysiology: WHO Classification and Mechanisms of Drug Interactions

The WHO ADR Classification

The WHO framework classifies ADRs into Types A through F. Types A and B dominate acute ED and exam practice. Type A (Augmented) reactions are predictable, dose-dependent extensions of the drug’s pharmacological effect and account for approximately 80% of all ADRs. Warfarin over-anticoagulation causing haemorrhage and beta-blocker-induced symptomatic bradycardia are archetypal examples. Type B (Bizarre) reactions are dose-independent, unpredictable, and often immunologically mediated: penicillin anaphylaxis and allopurinol-induced Stevens-Johnson syndrome fall here. Type D (Delayed) reactions, such as tardive dyskinesia following prolonged metoclopramide use, and Type E (End of use) reactions, including benzodiazepine withdrawal seizures, appear as FRCEM SBA clinical scenarios testing temporal reasoning and medication history scrutiny.

Pharmacokinetic Mechanisms

Drug interactions operate through pharmacokinetic or pharmacodynamic pathways. Pharmacokinetic interactions alter drug absorption, distribution, metabolism, or excretion. Absorption interactions are clinically underappreciated: antacids chelate quinolones and tetracyclines, reducing bioavailability significantly. Protein binding displacement transiently elevates free drug concentration; NSAIDs displacing warfarin from albumin binding sites is a classic but short-lived mechanism, quickly superseded by concurrent CYP2C9 inhibition.

The CYP450 system governs the metabolism of the majority of clinically relevant drugs and represents the single most important pharmacokinetic interaction mechanism for the SBA exam. Enzyme inhibitors (fluconazole, amiodarone, ciprofloxacin, erythromycin, metronidazole) increase plasma concentrations of co-administered drugs metabolised by the inhibited isoenzyme, often with rapid onset. Enzyme inducers (rifampicin, phenytoin, carbamazepine, St John’s Wort) accelerate metabolism of co-administered substrates, reducing efficacy; rifampicin and warfarin is the highest-yield induction pairing in the exam. Renal excretion interactions matter particularly for lithium: NSAIDs reduce renal prostaglandin synthesis, impairing lithium excretion and precipitating toxicity within days of co-prescription.

Pharmacodynamic Mechanisms

Pharmacodynamic interactions produce additive or synergistic effects at the level of the receptor or physiological system, independent of drug plasma concentrations. QTc prolongation is the paradigmatic example: antipsychotics (haloperidol, quetiapine), antiemetics (ondansetron, domperidone), certain antibiotics (azithromycin, ciprofloxacin), and antifungals can each prolong the QTc individually; in combination they substantially increase torsades de pointes risk. CNS and respiratory depression from concurrent opioid and benzodiazepine use is a pharmacodynamic interaction with a very steep harm curve. Additive bleeding risk from dual antiplatelet therapy plus anticoagulation is another scenario the SBA exam constructs with regularity.

ED Assessment and Management of Iatrogenic Presentations

Structured History and Medication Reconciliation

The medication history in a suspected iatrogenic presentation should encompass prescribed medications (with doses and recent changes), over-the-counter agents (including NSAIDs and herbal preparations), timing of any dose changes relative to symptom onset, renal or hepatic function changes, and intercurrent illness affecting drug handling. St John’s Wort, a potent CYP3A4 inducer, is a classic omission from self-reported medication lists and has caused clinically significant reductions in ciclosporin, antiretroviral, and oral contraceptive plasma levels.

Investigations

Focused investigation is guided by clinical suspicion. For narrow therapeutic index drugs, plasma drug levels are essential: digoxin, lithium, phenytoin, and theophylline levels can be requested urgently. A 12-lead ECG is mandatory where QTc prolongation, arrhythmia, or conduction abnormality is possible. Renal and hepatic function inform both the diagnosis and ongoing management. INR, blood glucose, and electrolytes are context-dependent but frequently relevant. The NHS TOXBASE database, accessed via the National Poisons Information Service, provides real-time, evidence-based guidance on toxidromes, thresholds for treatment, and antidote selection and should be accessed early in any uncertain toxicological presentation.

Management Principles and Selected Antidotes

Management follows the generic ED framework of resuscitation, definitive treatment, and safe disposition. Specific antidotes and reversal agents represent high-yield FRCEM SBA exam questions content. Warfarin over-anticoagulation with major haemorrhage requires four-factor prothrombin complex concentrate (4F-PCC) and intravenous vitamin K per NICE guidelines; fresh frozen plasma is no longer first-line for urgent reversal. Direct oral anticoagulant (DOAC) reversal uses idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors in life-threatening haemorrhage. Digoxin toxicity with life-threatening arrhythmia or haemodynamic compromise requires digoxin-specific antibody fragments (DigiFab). Opioid toxicity is reversed with naloxone, titrated to respiratory rate rather than consciousness level to avoid acute withdrawal. Hypoglycaemia from sulphonylureas requires prolonged observation and may require octreotide to suppress ongoing insulin secretion.

Angioedema deserves specific attention. ACE inhibitor-induced angioedema is a Type B bradykinin-mediated reaction, not IgE-mediated, and therefore does not respond to adrenaline, antihistamines, or corticosteroids. Airway management and discontinuation of the offending drug are the priority. This distinction is directly tested in the MRCEM Single Best Answer course lessons on angioedema and hereditary angioedema available on the EM Learning Centre homepage. Serotonin syndrome, precipitated by combinations including SSRIs with tramadol, linezolid, or triptans, presents with the classic triad of altered mental status, autonomic instability, and neuromuscular abnormalities (clonus, hyperreflexia, tremor); cyproheptadine and benzodiazepines are used for symptom management, with discontinuation of all serotonergic agents.

How the FRCEM SBA Exam Tests This Topic

The SBA format tests drug interaction knowledge through clinical vignettes rather than isolated pharmacology recall. A typical stem will describe a patient with a known background medication, a recently added or modified drug, and an acute presentation that the candidate must attribute to the interaction. The correct answer usually requires identifying the mechanism (inhibition, induction, pharmacodynamic synergy), selecting the appropriate investigation, or choosing the correct antidote while avoiding the plausible distractor (for example, giving FFP instead of 4F-PCC, or administering adrenaline for ACE inhibitor angioedema).

The RCEM curriculum maps this to the domains of pharmacological therapeutics, patient safety, and clinical assessment. Candidates should be comfortable interpreting ECGs with QTc prolongation, recognising toxidrome patterns, and knowing which patients require NPIS consultation. The FRCEM SBA exam questions in this domain often include one ethically nuanced distractor, such as delaying treatment to await full medication reconciliation, to probe clinical prioritisation skills.

Revision Pearls: High-Yield Facts for FRCEM SBA Practice Questions

1. Rifampicin is the most potent CYP450 inducer in clinical practice; it dramatically reduces warfarin, oral contraceptive, and antiretroviral plasma levels within days of commencement.
2. Lithium toxicity is precipitated by dehydration, renal impairment, and NSAIDs; early features include tremor and polyuria, and the therapeutic window is narrow (0.4 to 1.0 mmol/L).
3. ACE inhibitor angioedema is bradykinin-mediated, not histamine-mediated; adrenaline does not treat the underlying mechanism, though it may temporise airway oedema.
4. QTc greater than 500 ms confers substantial torsades de pointes risk; always review the full drug chart before prescribing additional QTc-prolonging agents in the ED.
5. Serotonin syndrome can be distinguished from neuroleptic malignant syndrome by its faster onset (hours versus days), presence of clonus and hyperreflexia, and association with serotonergic rather than dopaminergic drug exposure.
6. Metformin does not cause hypoglycaemia in isolation; perioperative or contrast-related lactic acidosis risk in the context of renal impairment is the more clinically relevant ADR.
7. Digoxin toxicity is potentiated by hypokalaemia; diuretic-induced electrolyte disturbance is a common and examinable precipitant of digoxin toxicity in patients on stable long-term therapy.

Common Pitfalls: Where Candidates Lose Marks

• Confusing histamine-mediated anaphylaxis with bradykinin-mediated ACE inhibitor angioedema and selecting adrenaline or antihistamines as the primary management for the latter.
• Failing to recognise that drug-induced QTc prolongation is an additive risk; dismissing a single agent as safe in isolation without considering the patient’s background medications.
• Selecting FFP over 4F-PCC for warfarin reversal in major haemorrhage, an outdated answer that reflects historical rather than current UK guideline-based practice.
• Misidentifying the temporal pattern of ADR types: Type D (delayed) reactions such as tardive dyskinesia appear long after exposure, not acutely.
• Overlooking St John’s Wort and other herbal or over-the-counter agents as enzyme inducers or inhibitors in the stem’s medication history.
• Applying naloxone at a dose that reverses analgesia and precipitates acute opioid withdrawal, rather than titrating to an adequate respiratory rate.

How EM Learning Centre Supports Your MRCEM Single Best Answer Revision

Pharmacology and iatrogenic presentations reward structured, repeated exposure to high-quality clinical scenarios, precisely the format used across the MRCEM Single Best Answer revision course at EM Learning Centre. The platform’s lessons on acute allergy, anaphylactoid reactions, angioedema in the Emergency Department, hereditary angioedema, and urticaria integrate the pharmacological mechanisms described in this article directly into clinically contextualised SBA-format questions, allowing you to apply, not merely recall, your knowledge under exam conditions.

Consistent practice with well-written FRCEM SBA practice questions, mapped to the current RCEM curriculum, remains the most evidence-informed approach to exam preparation. The question bank at EM Learning Centre is built by practising UK emergency physicians to reflect the standard, style, and clinical depth of the live exam, with detailed explanations that support both immediate learning and long-term retention. If medication side effects and interactions are a gap in your revision, the structured lessons on allergy and iatrogenic presentations are a logical starting point.

References

1. Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004;329:15. The BMJ
2. National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE Guideline NG5, 2015. NICE
3. Royal College of Emergency Medicine. RCEM Curriculum for Emergency Medicine. RCEM
4. Resuscitation Council UK. Emergency treatment of anaphylaxis: guidelines for healthcare providers, 2021. Resuscitation Council UK
5. NHS. TOXBASE and National Poisons Information Service clinical guidance. NHS
6. British National Formulary. Drug interactions and prescribing in renal impairment. British National Formulary